Gfi1 Inhibition and the Future of ALL Management

Author： Phelan James D.   Zweidler-McKay Patrick A.   Grimes H. Leighton  

Publisher： Optimal Clinical Ltd

ISSN： 2053-2091

Source： The Journal of OncoPathology, Vol.1, Iss.2, 2013-07, pp. : 27-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs

By          

International Journal of Oncology, Vol. 47, Iss. 4, 2015-01 ,pp. : 1230-1240

Spandidos Publications

Access to resources Recommend Favorite

Growth inhibition of Tax-activated human Jurkat leukemia T cells by all-trans retinoic acid requires JNK-1 inhibition

By    

Oncology Reports, Vol. 29, Iss. 1, 2013-01 ,pp. : 387-393

Spandidos Publications

Access to resources Recommend Favorite

Surgical Management of Breast Cancer in the Future

By von Smitten Karl  

Acta Oncologica, Vol. 39, Iss. 3, 2000-10 ,pp. : 437-439

Informa Healthcare

Access to resources Recommend Favorite

Outcomes Management: An Opportunity for Our Future

By Kennedy A.W.  

Gynecologic Oncology, Vol. 63, Iss. 2, 1996-11 ,pp. : 157-158

Academic Press

Access to resources Recommend Favorite

MDR1 inhibition: less resistance or less relevance?

By Garraway L.A.   Chabner B.  

European Journal of Cancer, Vol. 38, Iss. 18, 2002-12 ,pp. : 2337-2340

Elsevier

Access to resources Recommend Favorite